At a glance
ClinicalIndex Comparison RecordPhase 2Active· 35 enrolled
Drug / intervention
Copanlisib Hydrochloride +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations (PTEN Loss Allowed)
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Computed Tomography, and 2 other interventions for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 35 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation. Copanlisib may stop the growth of cancer cells by blocking PIK3, a protein needed for cell growth. Researchers hope to learn if copanlisib will shrink this type of cancer or stop its growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
201920202021202220232024202520262027
Enrollment StartJun 2018
Primary CompletionJan 2021
First PostedAug 2022
TodayJul 2026
Study CompletionJan 2027
First PostedAug 8, 2022
Enrollment StartJun 20, 2018
Primary CompletionJan 6, 2021
Study CompletionJan 15, 2027
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 3.9 years ago
Interventions
Biopsy Procedureprocedure
Undergo tumor biopsy
Computed Tomographyprocedure
Undergo CT
Copanlisib Hydrochloridedrug
Given IV
Magnetic Resonance Imagingprocedure
Undergo MRI